Slide1 - Management of Metastatic Disease
Slide2 - Metastatic Disease: No Prior Therapy
Slide3 - Metastatic Disease: No Prior Therapy (continued)
Slide4 - Metastatic Disease: No Prior Therapy (continued)
Slide5 -Metastatic Disease: No Prior Therapy (continued)
Slide6 - Metastatic Disease: No Prior Therapy (continued)
Slide7 - Metastatic Disease: No Prior Therapy (continued)
Slide8 - Metastatic Disease: No Prior Therapy (continued)
Slide9 - Metastatic Disease: No Prior Therapy (continued)
Slide10 - Metastatic Disease: No Prior Therapy (continued)
Slide11 - Metastatic Disease: No Prior Therapy (continued)
Slide12 - Metastatic Disease: No Prior Therapy (continued)
Slide13 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time
Slide14 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time (continued)
Slide15 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time (continued)
Slide16 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time (continued)
Slide17 - Metastatic Disease: Prior Therapy; 6-month PSA Doubling Time
Slide18 - Metastatic Disease: Prior Therapy; 6-month PSA Doubling Time (continued)
Slide19 - Metastatic Disease: Prior Therapy; 6-month PSA Doubling Time (continued)
Slide20 - Metastatic Disease: Prior Therapy; 6-month PSA Doubling Time (continued)
Slide21 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time
Slide22 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time (continued)
Slide23 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time (continued)
Slide24 - Metastatic Disease: Prior Therapy; 12-month PSA Doubling Time (continued)
Slide25 - Metastatic Disease: Prior Therapy; 6-month PSA Doubling Time
Slide26 - Metastatic Disease: Prior Therapy; 6-month PSA Doubling Time (continued)
Slide27 - Screening for Metastatic Disease
Slide28 - Incidence of Metastases on First Diagnosis
Slide29 - Clinical Use of Bisphosphonates
Slide30 - Sequencing of Therapy in Metastatic Disease
Slide31 - Sequencing of Therapy in Metastatic Disease (continued)
Slide32 - Sequencing of Therapy in Metastatic Disease (continued)
Slide33 - Perceptions of Chemotherapy for Prostate Cancer
Slide34 - Perceptions of Chemotherapy for Metastatic Prostate Cancer
Slide35 - Referrals to Medical Oncologists
Slide36 - Referrals to Medical Oncologists
Slide37 - Familiarity with Recent Clinical Trials of Chemotherapy for Prostate Cancer
Slide38 - Consultations with Medical Oncologists for Prostate Cancer
Slide39 - Discussing the Role of Chemotherapy in Prostate Cancer
Slide40 - Perceptions of Chemotherapy for Prostate Cancer
Slide41 - Definition of Hormone-Refractory Disease
